BDX
Becton, Dickinson and Co.
$192.00
장중 · Vol 22.7K · 52주 $127.59–$193.07 · 기준 2026. 8. 21. PM 3:59 ET
일봉 $187.57 · Aug 31, 2026
BDX 가격 추세
종가
$187.57
시가
$188.04
고가
$188.00
저가
$186.62
30초 브리핑
BDX 오늘의 판단 요약
보유 데이터를 비교 가능한 문장으로 해석한 요약입니다.
52주 범위의 98%
연중 고점권입니다. 추세 강도와 돌파 실패 위험을 함께 확인하세요.
Forward P/E 14.2배
선행 P/E가 낮아 시장은 이익 증가를 반영하고 있습니다.
20일 평균의 1.4배
거래량은 최근 평균 범위입니다.
2026-11-05
실적 전후 변동성 확대 가능성이 있으므로 컨센서스 범위와 옵션 기대변동을 함께 보세요.
펀더멘털 기준 Sep 1, 2026 · 규칙 기반 요약이며 투자 조언이 아닙니다.
핵심 통계
BDX 일봉·펀더멘털 스냅샷 기준 주요 지표
펀더멘털 스냅샷 Sep 1, 2026
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems. It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company has a strategic collaboration with ChemoGLO for the advancement of hazardous drug contamination testing in health care settings to improve the safety of health care workers. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.
1 Becton Drive · Franklin Lakes, NJ, United States · 직원 72,000명
시가총액
$51.24B
Trailing P/E
32.8
최근 12개월 이익 기준
Forward P/E
14.2
이익 증가 기대 반영
EPS (TTM)
$5.74
배당 수익률
2.22%
배당성향
72.5%
베타
0.26
시장보다 방어적
ROE
6.6%
P/B
2.10
EV/EBITDA
11.1
52주 범위
$127.59 – $193.07
현재 위치 98%
거래량
1.79M
20일 평균 1.29M · 1.4배
애널리스트 의견
매수 50%
총 14명 · 0m
DITM LEAPS Analysis
BDX 장기 DITM 콜옵션을 진입 적합도 순으로 비교
| Contract | Expiry | Strike | Price | Lev. | Delta | Extrinsic | Spread | IV | OI | Score | 상세 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BDX280121C00120000 | 1/21/28 · 1.4Y | $120.00 | $72.75 | 2.3x | 0.9028 | 6.4% | 6.19% | 41.20% | 25 | 84.43 | |
| BDX280121C00130000 | 1/21/28 · 1.4Y | $130.00 | $64.75 | 2.5x | 0.8761 | 10.3% | 6.95% | 39.78% | 10 | 79.04 | |
| BDX280121C00115000 | 1/21/28 · 1.4Y | $115.00 | $79.75 | 2.1x | 0.8954 | 8.3% | 5.64% | 48.52% | 0 | 78.03 | |
| BDX280121C00125000 | 1/21/28 · 1.4Y | $125.00 | $71.25 | 2.3x | 0.8742 | 11.4% | 6.32% | 45.52% | 1 | 74.77 | |
| BDX280121C00135000 | 1/21/28 · 1.4Y | $135.00 | $62.50 | 2.6x | 0.8561 | 15.0% | 4.80% | 40.62% | 6 | 74.64 | |
| BDX280121C00140000 | 1/21/28 · 1.4Y | $140.00 | $58.50 | 2.7x | 0.8343 | 17.8% | 10.26% | 41.92% | 9 | 69.68 | |
| BDX280121C00150000 | 1/21/28 · 1.4Y | $150.00 | $49.80 | 3.1x | 0.8129 | 23.5% | 7.23% | 36.35% | 20 | 68.19 | |
| BDX280121C00155000 | 1/21/28 · 1.4Y | $155.00 | $46.00 | 3.2x | 0.7919 | 28.0% | 10.87% | 36.27% | 6 | 61.89 | |
| BDX280121C00160000 | 1/21/28 · 1.4Y | $160.00 | $42.95 | 3.4x | 0.7725 | 34.5% | 9.08% | 35.32% | 44 | 59.85 |
재무제표
BDX 연간 손익·현금흐름·재무상태
매출 성장률
+8.2%
최근 연간 YoY
EPS 성장률
-1.9%
최근 연간 YoY
영업이익률
13.7%
최근 연간
FCF 마진
12.2%
잉여현금흐름 / 매출
매출 추세
순이익 추세
잉여현금흐름 추세
| 항목 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| 매출 | $21.84B+8.2% | $20.18B+4.2% | $19.37B+2.7% | $18.87B |
| 매출총이익 | $9.93B+8.8% | $9.13B+11.7% | $8.17B-3.6% | $8.48B |
| 영업이익 | $2.99B+4.6% | $2.86B+17.8% | $2.42B-2.1% | $2.48B |
| 순이익 | $1.68B-1.6% | $1.71B+14.9% | $1.48B-16.6% | $1.78B |
| 희석 EPS | $5.82-1.9% | $5.93+20.0% | $4.94-16.0% | $5.88 |
| EBITDA | $4.96B+2.8% | $4.82B+9.5% | $4.40B-0.2% | $4.41B |
| 영업현금흐름 | $3.43B-9.6% | $3.80B+27.0% | $2.99B+13.5% | $2.63B |
| 잉여현금흐름 | $2.67B-13.1% | $3.07B+45.2% | $2.12B+27.4% | $1.66B |
| 총자산 | $55.33B-3.4% | $57.29B+8.5% | $52.78B-0.3% | $52.93B |
| 총부채 | $19.18B-4.6% | $20.11B+26.6% | $15.88B-1.2% | $16.07B |
최신 연도 우선 · 작은 퍼센트는 직전 연도 대비 변화입니다.
캘린더
BDX 실적·배당 일정
매출 하단
$5.07B
EPS 하단
$4.03
매출 상단
$5.17B
배당 지급일
2026-09-30
D-29
실적 발표일
2026-11-05
D-65
EPS 상단
$4.11
매출 컨센서스
$5.11B
EPS 컨센서스
$4.07
배당락일
2026-09-09
D-8
최근 배당
| 배당락일 | 주당 배당 |
|---|---|
| Jun 9, 2026 | $1.0500 |
| Mar 10, 2026 | $1.0500 |
| Dec 8, 2025 | $0.8255 |
| Sep 8, 2025 | $0.8176 |
| Jun 9, 2025 | $0.8176 |
| Mar 10, 2025 | $0.8176 |
| Dec 9, 2024 | $0.8176 |
| Sep 9, 2024 | $0.7469 |
뉴스
BDX 관련 최신 기사
제품·기술The Peer-Group Mispricing Sitting On BSX Stock
This medical device maker posts elite numbers but wears a bargain-bin price tag, and the reason is a sudden crisis of confidence in its star products.
Trefis · Sep 1, 2026
제품·기술Two Recessions Couldn’t Stop These 4 Healthcare Stocks From Raising Dividends
Two brutal recessions wiped out dividends across the market, yet a handful of healthcare companies kept raising their payouts through every quarter of both downturns. Here are the four names that made it happen and whether their income streaks can survive what comes next.
24/7 Wall St. · Aug 31, 2026
일반Jim Cramer Calls This Mining Stock an Inflation Hedge “Just as Good as Crypto”
Jim Cramer just put a Brazilian mining giant in the same sentence as cryptocurrency, and his reasoning has everything to do with where he thinks inflation is headed next.
24/7 Wall St. · Aug 31, 2026
제품·기술Has BSX Stock Fallen Far Enough To Buy?
U.S. electrophysiology growth slowed sharply and standalone WATCHMAN referrals declined in the same window, leaving the rest of Boston Scientific unable to maintain its growth-stock multiple.
Trefis · Aug 27, 2026
제품·기술Time To Squeeze 14% Yield Out Of Battered BSX Stock?
For long-suffering owners of Boston Scientific, here’s how to get paid a meaningful cash income now, yours to keep no matter what, in exchange for capping your gains at a higher price.
Trefis · Aug 26, 2026
제품·기술The Floor Under BSX Stock Is Being Tested Again
Boston Scientific is back on familiar ground, but the business arriving this time is not the same. Will a history of strong bounces matter more than a future of weaker growth.
Trefis · Aug 25, 2026
- 일반
Waters' Q4 Guide Conservative, 2027 Growth Could Reach High Single Digits, RBC Says
Waters' (WAT) Q4 guidance is conservative, as there is no inherent reason for legacy Waters' growth
MT Newswires · Aug 24, 2026
실적Can Teleflex's OEM Sale and Higher EPS Outlook Reshape 2026 Returns?
TFX's $1.5B OEM sale cuts leverage and lifts 2026 EPS guidance, but weaker growth and margin pressure keep the outlook measured.
Zacks · Aug 24, 2026
제품·기술Becton Dickinson (BDX) Could Be 1% Overvalued As PREVENT Trial Enrollment Ends
Becton Dickinson (BDX) is in focus after announcing completion of patient enrollment in its PREVENT clinical trial for Phasix Mesh, a potential first in class option for preventing incisional hernias. See our latest analysis for Becton Dickinson. The PREVENT milestone comes after a series of recent updates around Becton Dickinson, including new quality leadership appointments, conference appearances and a recall-related correction notice. It also comes against a backdrop of a 30 day share...
Simply Wall St. · Aug 21, 2026
- 실적
Becton Dickinson (BDX) Stock Could Be A Bargain On Cash Flow But Full On Broader Checks
Becton Dickinson stock has delivered a 25.4% return over the past year, while current valuation checks suggest the shares may still trade below an estimate of intrinsic value based on a Discounted Cash Flow (DCF) approach and earnings multiples. Over the last 12 months, Becton Dickinson has returned 25.4%, which puts recent gains in focus when assessing how much upside may remain. Progress on the PREVENT clinical trial can support long term cash flow expectations, while the recent recall of...
Simply Wall St. · Aug 21, 2026
홀더
BDX 내부자·기관 보유 현황
최신 보고 목록 기준이며 실제 거래 시점과 보고일 사이에는 시차가 있습니다.
기관 보유
99.6%
기관 보유 (유동주식)
100.1%
내부자 보유
0.4%
기관 수
1,919
주요 기관 홀더
| 홀더 | 주식 수 | 평가액 | 지분 | 변동 | 보고일 |
|---|---|---|---|---|---|
| Blackrock Inc. | 24.59M | $4.63B | 8.9% | -6.0% | Jun 30, 2026 |
| Vanguard Capital Management LLC | 17.99M | $3.38B | 6.5% | -2.7% | Jun 30, 2026 |
| State Street Corporation | 15.00M | $2.82B | 5.4% | 8.5% | Jun 30, 2026 |
| Vanguard Portfolio Management LLC | 14.97M | $2.82B | 5.4% | -2.2% | Jun 30, 2026 |
| First Eagle Investment Management, LLC | 13.82M | $2.60B | 5.0% | 15.8% | Jun 30, 2026 |
| Invesco Ltd. | 8.90M | $1.67B | 3.2% | -12.5% | Jun 30, 2026 |
| Massachusetts Financial Services Co. | 8.65M | $1.63B | 3.1% | -5.0% | Jun 30, 2026 |
| Geode Capital Management, LLC | 8.14M | $1.53B | 2.9% | 14.5% | Jun 30, 2026 |
| Franklin Resources, Inc. | 7.01M | $1.32B | 2.5% | 30.7% | Jun 30, 2026 |
| Wellington Management Group, LLP | 6.36M | $1.20B | 2.3% | -3.9% | Jun 30, 2026 |
면책조항: 증시가격은 모든 주식 시장의 최신 증시가격을 표시하는 것은 아니며, 정보가 지연되거나 잘못될 수 있습니다. 거래 목적이나 조언이 아닌 정보 제공 목적으로만 제공됩니다.